已收盤 11-20 16:00:00 美东时间
-0.510
-4.54%
11月18日,Gossamer Bio(GOSS)收涨0.55%,报11.04美元,成交额239.31万美元,市值6752.49万美元。 行情数据 • 开盘价...
11-18 08:13
今日重点评级关注:韦德布什:维持Cullinan Therapeutics"跑赢大市"评级,目标价从42美元升至44美元;HC Wainwright & Co.:维持WhiteFiber"买入"评级,目标价从34美元升至36美元
11-12 19:19
Wedbush analyst Laura Chico maintains Gossamer Bio (NASDAQ:GOSS) with a Neutral and lowers the price target from $80 to $32.
11-11 22:14
Gossamer Bio shares are trading lower after the company reported mixed Q3 financial results.
11-11 05:36
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(7.36) per share which missed the analyst consensus estimate of $(3.68) by 100 percent. This is a 3404.76 percent decrease over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $38.431 million...
11-11 05:17
11月10日,Gossamer Bio(GOSS)收涨8.96%,报10.64美元,成交额256.14万美元,市值6510.88万美元。 行情数据 • 开盘价...
11-10 08:18
Processa Pharmaceuticals announced key leadership appointments to support its growth, including Gregory Flesher as Chief Operating Officer, Craig Coburn, Ph.D., as Executive Vice President, Head of Research, Ashley Hall, J.D., as Executive Vice President, Development, and Michael P. Cruse as Executive Vice President, Business Operations. These appointments follow the company's July 2026 acquisition of Vidya Therapeutics. Processa is advancing its...
11-04 13:00
11月3日,Gossamer Bio(GOSS)收跌8.96%,报9.45美元,成交额182.69万美元,市值5779.94万美元。 行情数据 • 开盘价:1...
11-03 08:17
Processa Pharmaceuticals announced FDA clearance for a Phase 2 study of VT-7208 in chronic spontaneous urticaria (CSU), with additional Phase 2 studies planned for food allergy and relapsing multiple sclerosis. The company expanded its pipeline through a collaboration with Generian Pharmaceuticals for a novel neonatal Fc receptor antagonist program. Sheila Gujrathi, M.D., was appointed Executive Chair of the Board of Directors, and the company ex...
10-29 12:00
Gossamer Bio ( ($GOSS) ) has issued an announcement. At a special meeting held ...
10-29 04:47